Oct. 2 Company Quick Takes: Merck, Immunovant, PureTech-Ariya, Viscient-Organovo and Durect

China approves Keytruda monotherapy for 1L NSCLC
China's National Medical Products Administration approved PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) as a monotherapy for first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients whose tumors express

Read the full 420 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE